Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy
Brief Summary: This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo, Drug: DMARD Therapy | Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: etanercept, Drug: DMARD Therapy | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: DMARD Therapy; Assigned to Arm(s): Etanercept, Placebo
B: Arm Label: DB Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double-blind Placebo | Arm Label: DB adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab | Arm Label: DB Adalimumab/OL Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab, Biological: Open-label Adalimumab | Arm Label: DB Placebo/OL Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Double-blind Placebo, Biological: Open-label Adalimumab | Arm Label: DB Adalimumab/RE OL Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab, Biological: Open-label Adalimumab, Biological: Open-labelAdalimumabRescue | Arm Label: DB Placebo/RE OL Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Double-blind Placebo, Biological: Open-label Adalimumab, Biological: Open-labelAdalimumabRescue | Intervention Type: BIOLOGICAL; Name: Double-blind adalimumab; Assigned to Arm(s): DB Adalimumab/OL Adalimumab, DB Adalimumab/RE OL Adalimumab, DB adalimumab | Intervention Type: DRUG; Name: Double-blind Placebo; Assigned to Arm(s): DB Placebo, DB Placebo/OL Adalimumab, DB Placebo/RE OL Adalimumab | Intervention Type: BIOLOGICAL; Name: Open-label Adalimumab; Assigned to Arm(s): DB Adalimumab/OL Adalimumab, DB Adalimumab/RE OL Adalimumab, DB Placebo/OL Adalimumab, DB Placebo/RE OL Adalimumab | Intervention Type: BIOLOGICAL; Name: Open-labelAdalimumabRescue; Assigned to Arm(s): DB Adalimumab/RE OL Adalimumab, DB Placebo/RE OL Adalimumab
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 3
D: Arm Label: Tocilizumab 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Placebo to adalimumab | Arm Label: Adalimumab 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab, Drug: Placebo to tocilizumab | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to tocilizumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to adalimumab; Assigned to Arm(s): Tocilizumab 8 mg/kg

Answer: A